Vyne Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

YARROW BIOSCIENCE

04/11/2022 19:35

* Vyne Therapeutics Inc  VYNE.OQ   VYNE.O  is expected
to show a
fall in quarterly revenue when it reports  results on November 8
(estimated). 
    * The Wilmington Delaware-based  company is expected to
report  a
96.7% decrease in revenue to $133.33 thousand from $4.09 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Vyne Therapeutics
Inc is
for a loss of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vyne
Therapeutics
Inc is $4​, above​ its last closing price of $0.27. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.17       -0.17      -0.13     Beat    23.5
 Mar. 31 2022  -0.18       -0.16      -0.14     Beat    15.2
 Dec. 31 2021  -0.20       -0.24      -0.20     Beat    15.5​
 Sep. 30 2021  -0.32       -0.32      -0.36     Missed  -11.6
 ​​Jun.        -0.35       -0.35      -0.35     Met     1.1
 30 2021                                                
 Mar. 31 2021  -0.39       -0.41      -0.37     Beat    9.3​
 Dec. 31 2020  -0.53       -0.54      -0.55     Missed  -2.6
 Sep. 30 2020  -0.68       -0.67      -0.60     Beat    10.3
 This summary was machine generated November 4 at 19:34 GMT.  All
figures in US dollars  unless otherwise stated